CRC 1453 Seminar Series - Distinguished Speaker Professor Katalin Susztak – Perelman School of Medicine, University of Pennsylvania, USA
Topic: Going from kidney function GWAS to kidney disease mechanism
CRC 1453 Seminar Series - Distinguished Speaker Professor Friedhelm Hildebrandt – Harvard Medical School; Boston Children’s Hospital
Topic: Precision Medicine in Early-Onset Chronic Kidney Disease
Polycystic Disease – From Model Organisms to Novel Therapies
Funding: 2008 - 2018
Polycystic kidney disease (PKD) is a group of diseases characterized by dilated or cystic tubular segments of the kidney accompanied by a wide spectrum of abnormalities in other organs. Cystic tubules fail to perform their physiological function properly, resulting in fluid retention, high blood pressure and kidney failure requiring dialysis or transplantation. Over the last decade, more than 20 genes have been identified that cause polycystic kidney disease. The most common form, autosomal dominant polycystic kidney disease (ADPKD), affects between 1/500 and 1/1000 people. PKD is an important health care problem. It is responsible for ~5% of all individuals with end stage kidney failure.
The Clinical Research Unit 201 employs a multidisciplinary approach to bridge the gap between experimental research at the molecular level and optimal patient care.